Abstract
AbstractHiBit is an engineered luciferase’s 11 amino acid component that can be introduced as a tag at either terminus of a protein of interest. When the LgBit component and a substrate are present, HiBit and LgBit dimerise forming a functional luciferase. The HiBit technology has been extensively used for high-throughput protein turnover studies in cells. Here, we have adapted the use of the HiBit technology to quantify mRNA translation temporallyin vitroin the rabbit reticulocyte system andin celluloin HEK293 cells constitutively expressing LgBit. The assay system can detect differences in Cap, 5’UTR, modified nucleotide composition, coding sequence optimisation and poly(A) length. Importantly, using these assays we established the optimal mRNA composition varied depending on the encoded protein of interest, highlighting the importance of screening methods tailored to the protein of interest, and not reliant on reporter proteins. Our findings demonstrated that HiBit can be easily and readily adapted to monitor mRNA translation and offers a novel and highly favourable method for the development of mRNA-based therapeutics.Graphical abstract
Publisher
Cold Spring Harbor Laboratory
Reference82 articles.
1. mRNA-based therapeutics: powerful and versatile tools to combat diseases;Signal Transduction and Targeted Therapy,2022
2. Characterization of a messenger RNA polynucleotide vaccine vector;Cancer Res,1995
3. mRNA vaccines — a new era in vaccinology
4. mRNA therapeutics: New vaccination and beyond;Fundamental Research,2023
5. The plasticity of mRNA translation during cancer progression and therapy resistance